Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Family experiences of receiving treatment recommendations in a precision medicine trial for poor-prognosis childhood cancer.

NPJ genomic medicine·2026
Same author

Digital Health Tools Embedded in a Cancer Genetics Clinic: Observational Study.

JMIR formative research·2026
Same author

Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium.

European journal of human genetics : EJHG·2026
Same author

Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma.

Nature genetics·2025
Same author

Parent and Patient Proxies' Preferences on Whole-body MRI Techniques for Cancer Predisposition Syndromes' Surveillance.

Journal of pediatric hematology/oncology·2025
Same author

Correction: Update on Whole-Body MRI Surveillance for Pediatric Cancer Predisposition Syndromes.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Related Experiment Video

Updated: May 30, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

Li-fraumeni syndrome.

David Malkin1

  • 1Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.

Genes & Cancer
|July 23, 2011
PubMed
Summary

Li-Fraumeni syndrome (LFS) involves inherited mutations in the p53 gene, leading to various cancers. Additional genetic factors influence LFS, explaining its complex presentation and variable outcomes in affected families.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition disorder.
  • It is primarily linked to germline mutations in the p53 tumor suppressor gene.
  • The clinical presentation of LFS, including cancer types and onset, is complex and not fully explained by p53 mutations alone.

Purpose of the Study:

  • To review the clinical and genetic definitions of Li-Fraumeni syndrome.
  • To explore genetic factors that modify the LFS phenotype.
  • To understand genotype-phenotype correlations in LFS and other familial cancer syndromes.

Main Methods:

  • Review of existing literature on Li-Fraumeni syndrome.
  • Analysis of genetic factors contributing to LFS phenotype variability.
Keywords:
Li-Fraumeni syndromecancer predispositiongermline p53 mutations

More Related Videos

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence
06:23

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence

Published on: January 17, 2025

Related Experiment Videos

Last Updated: May 30, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence
06:23

Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence

Published on: January 17, 2025

  • Examination of p53 mutations, polymorphisms, copy number variation, and telomere length in LFS.

    • Main Results:

    • Germline p53 mutations are central to LFS, but additional genetic events modify the phenotype.
    • Intragenic polymorphisms, p53 pathway gene variations, copy number alterations, and telomere attrition contribute to LFS complexity.
    • These factors help explain the diverse tumor types, early cancer onset, and varied clinical outcomes observed in LFS families.

    Conclusions:

    • The LFS phenotype is shaped by a combination of germline p53 mutations and other genetic modifiers.
    • Understanding these modifiers is crucial for explaining the full spectrum of LFS.
    • Insights from LFS can inform the study of other hereditary cancer syndromes.